Rapid Improvement of Fatigue and Sleep in Active Rheumatoid Arthritis with Anti-TNF Therapy: A Retrospective Observational Study

Objective: Patients with rheumatoid arthritis (RA) suffer from high burdens of fatigue and poor sleep quality which persist even when joint inflammation is controlled. We aimed to retrospectively evaluate the 3-month impact of initiating anti-TNF therapy initiation on fatigue sleep quality and functional status in patients with active RA. Methods: We conducted a 3-month single-center retrospective cohort study reviewing the records of 39 patients with active RA (Disease Activity Score 28 [DAS28] > 5.1) despite stable csDMARDs. A matched group of 36 healthy controls was used for baseline comparisons. Patients had initiated adalimumab, etanercept, or infliximab. Assessments had been performed at baseline and 3 months using the DAS28 (disease activity), Health Assessment Questionnaire (HAQ), Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Inventory (BDI). 31 patients had completed the 3-month follow-up and had complete data for analysis. Results: At 3 months, patients showed significant clinical improvement. Mean DAS28 decreased from 5.5 ± 1.2 to 3.3 ± 1.6 (p < 0.001) and 39% (12/31) achieved remission. Significant improvements were seen in patient-reported outcomes. The mean MFSI-SF total fatigue score decreased from 27.6 to 10.4 (p < 0.001) and the mean global PSQI score improved from 9.5 to 7.0 (p < 0.001). Functional status (HAQ) and depressive symptoms (BDI) also improved significantly (both p < 0.001). At baseline, fatigue strongly correlated with poor sleep (r=0.626), depression (r=0.674), and HAQ (r=0.656). Improvement in fatigue correlated moderately with improvement in depression (Δ-BDI r=0.571). Conclusion: Anti-TNF therapy provides rapid and significant improvements not only in clinical disease activity but also in the key patient-reported burdens of fatigue, sleep quality, and depression within three months of initiation. Keywords: rheumatoid arthritis, anti-TNF therapy, fatigue, sleep quality,

Authors

Institutions

Publication Details

Journal
Cukurova Anestezi ve Cerrahi Bilimler Dergisi
Published
2025-12-31
DOI
https://doi.org/10.36516/jocass.1818590
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rapid Improvement of Fatigue and Sleep in Active Rheumatoid Arthritis with Anti-TNF Therapy: A Retrospective Observational Study

A. Bilgici, Bora Uzuner, Sertac Ketenci, Ender Salbaş
Cukurova Anestezi ve Cerrahi Bilimler Dergisi
Rheumatoid Arthritis Research and Therapies
article

Rapid Improvement of Fatigue and Sleep in Active Rheumatoid Arthritis with Anti-TNF Therapy: A Retrospective Observational Study

A. Bilgici, Bora Uzuner, Sertac Ketenci, Ender Salbaş
article en

Abstract

Objective: Patients with rheumatoid arthritis (RA) suffer from high burdens of fatigue and poor sleep quality which persist even when joint inflammation is controlled. We aimed to retrospectively evaluate the 3-month impact of initiating anti-TNF therapy initiation on fatigue sleep quality and functional status in patients with active RA. Methods: We conducted a 3-month single-center retrospective cohort study reviewing the records of 39 patients with active RA (Disease Activity Score 28 [DAS28] > 5.1) despite stable csDMARDs. A matched group of 36 healthy controls was used for baseline comparisons. Patients had initiated adalimumab, etanercept, or infliximab. Assessments had been performed at baseline and 3 months using the DAS28 (disease activity), Health Assessment Questionnaire (HAQ), Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Inventory (BDI). 31 patients had completed the 3-month follow-up and had complete data for analysis. Results: At 3 months, patients showed significant clinical improvement. Mean DAS28 decreased from 5.5 ± 1.2 to 3.3 ± 1.6 (p < 0.001) and 39% (12/31) achieved remission. Significant improvements were seen in patient-reported outcomes. The mean MFSI-SF total fatigue score decreased from 27.6 to 10.4 (p < 0.001) and the mean global PSQI score improved from 9.5 to 7.0 (p < 0.001). Functional status (HAQ) and depressive symptoms (BDI) also improved significantly (both p < 0.001). At baseline, fatigue strongly correlated with poor sleep (r=0.626), depression (r=0.674), and HAQ (r=0.656). Improvement in fatigue correlated moderately with improvement in depression (Δ-BDI r=0.571). Conclusion: Anti-TNF therapy provides rapid and significant improvements not only in clinical disease activity but also in the key patient-reported burdens of fatigue, sleep quality, and depression within three months of initiation. Keywords: rheumatoid arthritis, anti-TNF therapy, fatigue, sleep quality,

Cukurova Anestezi ve Cerrahi Bilimler DergisiVol. 8(4)
Balıkesir University (TR), Ondokuz Mayıs University (TR)
No poverty
Openalex Percentile: Top 25%
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.